Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib in Moderate to Severe Alopecia Areata
NCT06278402Phase 3Completed
- Sponsor
- Jinnah Hospital
- Start
- Jul 2023
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tofacitinib oral solution in alopecia areata, alopecia totalis (AT) and alopecia universalis (AU), sponsored by Jinnah Hospital. Primary endpoint: Severity of Alopecia Tool Score Response at 6 months. Started Jul 2023; status: completed.
02
Drugs
tofacitinib oral solution
03
Conditions
alopecia areataalopecia totalis (AT)alopecia universalis (AU)
Beyond the preview
Go deeper on NCT06278402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06278402.